aristolochic acid i has been researched along with Kidney Diseases in 146 studies
aristolochic acid I: phospholipase A inhibitor
aristolochic acid A : An aristolochic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to investigate the roles of aristolochic acid I (AA-I) and hypokalemia in acute aristolochic acid nephropathy (AAN)." | 7.88 | Effects of aristolochic acid I and/or hypokalemia on tubular damage in C57BL/6 rat with aristolochic acid nephropathy. ( Han, SW; Kim, J; Kim, WY; Park, MH; Yi, JH, 2018) |
| "To investigate the therapeutic effects of endothelin receptor antagonist (bosentan) and angiotensin II type 1 receptor antagonist (valsartan) on renal interstitial fibrosis of rats with chronic aristolochic acid nephropathy (CAAN)." | 7.73 | [The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy]. ( Chen, YP; Dong, HR; Qiu, CB; Zhang, C, 2005) |
| "Bortezomib (BZM) is a proteasome inhibitor used for the treatment of multiple myeloma (MM)." | 5.46 | The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1. ( Chiga, M; Isobe, K; Mandai, S; Mori, T; Nomura, N; Rai, T; Sohara, E; Uchida, S; Yui, N; Zeniya, M, 2017) |
| "This study was designed to investigate the roles of aristolochic acid I (AA-I) and hypokalemia in acute aristolochic acid nephropathy (AAN)." | 3.88 | Effects of aristolochic acid I and/or hypokalemia on tubular damage in C57BL/6 rat with aristolochic acid nephropathy. ( Han, SW; Kim, J; Kim, WY; Park, MH; Yi, JH, 2018) |
| "To study the protective effects of Yishen Ruanjian Power (YRP) on renal interstitial fibrosis in rats with chronic aristolochic acid induced nephropathy (CAAN)." | 3.73 | [Protective effects of yishen ruanjian power on renal interstitial fribrosis in chronic aristolochic acid induced nephropathy rat model]. ( Chen, YP; Dong, H; Yang, YF; Zhang, C, 2005) |
| "To investigate the therapeutic effects of endothelin receptor antagonist (bosentan) and angiotensin II type 1 receptor antagonist (valsartan) on renal interstitial fibrosis of rats with chronic aristolochic acid nephropathy (CAAN)." | 3.73 | [The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy]. ( Chen, YP; Dong, HR; Qiu, CB; Zhang, C, 2005) |
| "As most patients progress to ESRD, need for renal replacement therapy, as either dialysis or kidney transplant, usually ensues." | 2.52 | Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment. ( Luciano, RL; Perazella, MA, 2015) |
| "Aristolochic acid I (AA-I) was absorbed and distributed quickly in vivo, the plasma concentration-time curve were fit with the open two-compartment model and one-compartment model, respectively." | 2.43 | [Advances in studies on pharmacokinetics of aristolochic acid I]. ( Sun, QS; Wang, G; Wang, ZM, 2006) |
| " However, the same AA-IVa dosage exhibited almost no nephrotoxicity and does not trigger RIF." | 1.91 | Differences in p38-STAT3-S100A11 signaling after the administration of aristolochic acid I and IVa may account for the disparity in their nephrotoxicity. ( Han, J; Li, C; Liang, A; Liu, C; Liu, S; Meng, J; Pan, C; Tang, X; Tian, J; Wang, D; Wang, F; Wang, L; Wang, Y; Xian, Z; Yi, Y; Zhang, Y; Zhao, Y, 2023) |
| " While the toxicity of AA-I and AA-II is relatively clear, there are marked differences in the toxic effects of different types of aristolochic acid analogues (AAAs)." | 1.91 | Study on the difference and correlation between the contents and toxicity of aristolochic acid analogues in Aristolochia plants. ( Han, J; Li, C; Liang, A; Liu, C; Liu, M; Liu, S; Meng, J; Pan, C; Qin, S; Tang, X; Tian, J; Wang, F; Wang, L; Xian, Z; Yi, Y; Zhang, Y; Zhao, Y, 2023) |
| " However, AA-containing herbs are highly safe in combination with berberine (Ber)-containing herbs in traditional medicine, suggesting the possible neutralizing effect of Ber on the toxicity of AA." | 1.62 | Berberine-Based Heterogeneous Linear Supramolecules Neutralized the Acute Nephrotoxicity of Aristolochic Acid by the Self-Assembly Strategy. ( Feng, Y; Guo, W; Huang, G; Huang, X; Lei, H; Li, T; Li, Y; Tian, X; Wang, P; Xu, A; Yuan, K; Zhao, L; Zhen, J, 2021) |
| "Renal fibrosis is a progressive pathological process that eventually leads to end-stage renal failure with limited therapeutic options." | 1.56 | Human umbilical cord mesenchymal stem cell attenuates renal fibrosis via TGF-β/Smad signaling pathways in vivo and in vitro. ( He, D; Hu, D; Lin, T; Liu, B; Liu, X; Long, C; Shen, L; Wei, G; Xiang, H; Xu, T; Yu, Y; Zhang, D; Zhang, Y; Zhou, Y, 2020) |
| " The toxic components are structurally related nitrophenanthrene carboxylic acids, i." | 1.51 | Comparison of Aristolochic acid I derived DNA adduct levels in human renal toxicity models. ( Bastek, H; Beneke, S; Dietrich, DR; Mangerich, A; Stemmer, K; Zubel, T, 2019) |
| "Renal interstitial fibrosis is one of the most typical features of AAN." | 1.48 | The potential role of aquaporin 1 on aristolochic acid I induced epithelial mesenchymal transition on HK-2 cells. ( Li, J; Li, Y; Mao, Y; Peng, X; Yu, F; Zhang, M; Zhang, X, 2018) |
| " The reduced nitric oxide (NO) bioavailability reported in AAN might contribute to renal function impairment and progression of the disease." | 1.46 | Restored nitric oxide bioavailability reduces the severity of acute-to-chronic transition in a mouse model of aristolochic acid nephropathy. ( Botton, O; Caron, N; Colombaro, V; Declèves, AE; Habsch, I; Jadot, I; Martin, B; Nortier, J, 2017) |
| "Bortezomib (BZM) is a proteasome inhibitor used for the treatment of multiple myeloma (MM)." | 1.46 | The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1. ( Chiga, M; Isobe, K; Mandai, S; Mori, T; Nomura, N; Rai, T; Sohara, E; Uchida, S; Yui, N; Zeniya, M, 2017) |
| "Aristolochic acid I (AAI) is a plant alkaloid causing aristolochic acid nephropathy, Balkan endemic nephropathy and their associated urothelial malignancies." | 1.42 | A Mechanism of O-Demethylation of Aristolochic Acid I by Cytochromes P450 and Their Contributions to This Reaction in Human and Rat Livers: Experimental and Theoretical Approaches. ( Arlt, VM; Bárta, F; Hodek, P; Levová, K; Martínek, V; Schmeiser, HH; Stiborová, M, 2015) |
| " The nephropathy was induced using intravenous injections of aristolochic acid at a dosage of 10 mg/kg per day for 5 days and was characterized biochemically and histologically." | 1.39 | Urinary d-lactate levels reflect renal function in aristolochic acid-induced nephropathy in mice. ( Chen, SM; Huang, TC; Lee, JA; Li, YC, 2013) |
| "Aristolochic acid I (ALA-I) was measured by ultra-high-pressure liquid chromatography/ tandem mass spectrometry (UHPLC-MS/MS) and heavy metals in blood samples were analysed by Agilent 7500C inductively coupled plasma-mass spectrometry." | 1.39 | Association of blood lead and mercury with estimated GFR in herbalists after the ban of herbs containing aristolochic acids in Taiwan. ( Chen, PC; Chou, SA; Hwang, YH; Kao, TW; Kuo, CH; Lin, HH; Lo, TC; Yang, HY, 2013) |
| " The chronic AAN patients took the lowest AA-I dose per day but with the longest period and the highest cumulative dosage and exhibited a very large range of eGFR changing rate (from -21." | 1.38 | Aristolochic acid nephropathy: variation in presentation and prognosis. ( Cai, SQ; Li, XM; Meng, LQ; Su, T; Wang, HY; Wang, X; Yang, L; Zou, WZ, 2012) |
| "Interstitial fibrosis is an inevitable outcome of all kinds of progressive chronic kidney disease (CKD)." | 1.38 | Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. ( Chen, G; Chen, H; Liu, F; Liu, H; Peng, Y; Sun, L; Wang, C, 2012) |
| " The symptoms were observed in rats that were dosed with AA at a dosage of 10 mg/kg/day for 1 month." | 1.37 | Proteomics investigation on aristolochic acid nephropathy: a case study on rat kidney tissues. ( Cai, Z; Chan, YW; Guo, L; Liu, N; Mak, YF; Poon, WT; Wu, HZ, 2011) |
| "Aristolochic acid I (AAI) is the major toxic component of aristolochic acid that causes aristolochic acid nephropathy and Balkan endemic nephropathy." | 1.37 | Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity. ( Chen, M; Gong, L; Li, Y; Luan, Y; Pan, G; Qi, X; Ren, J; Wu, Y; Xiao, Y; Xing, G; Xue, X; Yao, J, 2011) |
| " These results indicate that hepatic P450s play an important role in metabolizing aristolochic acid I into less toxic metabolites and thus have a detoxification role in aristolochic acid I-induced kidney injury." | 1.35 | Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. ( Ge, M; Gu, J; Li, L; Li, Y; Liu, L; Luo, H; Qi, X; Ren, J; Wang, C; Wang, H; Wu, X; Xiao, Y; Xie, T; Xue, X; Zhang, Y, 2008) |
| "This study was designed to compare the possible toxic effects of Longdan Xieganwan and three different Aristolochia species, i." | 1.35 | Comparative 28-day repeated oral toxicity of Longdan Xieganwan, Akebia trifoliate (Thunb.) koidz., Akebia quinata (Thunb.) Decne. and Caulis aristolochiae manshuriensis in mice. ( Gong, L; Guan, S; Li, Y; Liu, Y; Lu, H; Qi, X; Ren, J; Wu, X; Xiao, Y; Xue, X; Zhang, Y, 2008) |
| " To distinguish the component(s) of AA responsible for these varied toxic effects, we administered 2." | 1.34 | Selective toxicity of aristolochic acids I and II. ( Dong, H; Grollman, AP; Miller, F; Shibutani, S; Suzuki, N; Ueda, S, 2007) |
| "0mg/kg) of aristolochic acid sodium (AANa) to 4 respective groups of rabbits (n=6 for each dose), linear relationships between the doses of AA I and AA II and the area under the plasma concentration curve (AUC) were found to exist (p<0." | 1.34 | Pharmacokinetics and nephrotoxicity of aristolochic acid in rabbits. ( Chen, SM; Fan, MY; Ho, Y; Hsu, KY; Tseng, CC, 2007) |
| " Pattern recognition analysis indicated that the renal proximal tubule lesion was the main damage induced by AA, and the renal toxicity induced by AA was a progressive course with the accumulation of dosage by monitoring the toxicological processes from onset, development and part-recovery." | 1.33 | NMR-based metabonomic study on the subacute toxicity of aristolochic acid in rats. ( Li, X; Liao, P; Ni, J; Pei, F; Wu, H; Zhang, X, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.68) | 18.7374 |
| 1990's | 8 (5.48) | 18.2507 |
| 2000's | 38 (26.03) | 29.6817 |
| 2010's | 68 (46.58) | 24.3611 |
| 2020's | 31 (21.23) | 2.80 |
| Authors | Studies |
|---|---|
| Xian, Z | 3 |
| Tian, J | 4 |
| Zhang, Y | 8 |
| Meng, J | 3 |
| Zhao, Y | 5 |
| Li, C | 5 |
| Yi, Y | 4 |
| Han, J | 4 |
| Liu, S | 3 |
| Wang, L | 4 |
| Pan, C | 3 |
| Wang, D | 2 |
| Wang, F | 4 |
| Liang, A | 4 |
| Wang, Y | 6 |
| Wang, Z | 1 |
| Wu, Z | 1 |
| Chen, M | 2 |
| Dong, D | 1 |
| Yu, P | 1 |
| Lu, D | 1 |
| Wu, B | 1 |
| Jiang, W | 1 |
| Xu, C | 1 |
| Xu, S | 2 |
| Su, W | 1 |
| Du, C | 1 |
| Dong, J | 1 |
| Feng, R | 1 |
| Huang, C | 1 |
| Li, J | 3 |
| Ma, T | 1 |
| Zhang, Q | 2 |
| Luo, P | 1 |
| Chen, J | 2 |
| Yang, C | 1 |
| Xia, F | 1 |
| Zhang, J | 3 |
| Tang, H | 1 |
| Liu, D | 1 |
| Gu, L | 1 |
| Shi, Q | 1 |
| He, X | 1 |
| Yang, T | 1 |
| Wang, J | 1 |
| Yang, Y | 4 |
| Ge, FL | 1 |
| Zhan, XY | 1 |
| Mu, WQ | 1 |
| Li, ZY | 1 |
| Lin, L | 1 |
| Wei, ZY | 1 |
| Bai, ZF | 1 |
| Sun, Q | 1 |
| Xiao, XH | 1 |
| Chan, KJ | 1 |
| Chan, W | 4 |
| Wang, X | 5 |
| Jia, P | 1 |
| Ren, T | 1 |
| Zou, Z | 1 |
| Shi, Y | 1 |
| Bao, S | 1 |
| Li, Y | 7 |
| Fang, Y | 1 |
| Ding, X | 1 |
| Liu, Z | 2 |
| Shi, B | 1 |
| Xu, Q | 1 |
| Gao, H | 1 |
| Ma, J | 1 |
| Jiang, X | 1 |
| Yu, W | 2 |
| Das, T | 1 |
| Mukerjee, N | 1 |
| Ghosh, A | 1 |
| Lorenzo, JM | 1 |
| Dhama, K | 1 |
| Dey, A | 1 |
| Au, CK | 1 |
| Ham, YH | 1 |
| Komatsu, M | 1 |
| Funakoshi, T | 1 |
| Aki, T | 1 |
| Unuma, K | 1 |
| Uemura, K | 1 |
| Chan, CK | 1 |
| Pavlović, NM | 1 |
| Liu, C | 2 |
| Tang, X | 2 |
| Qin, S | 1 |
| Liu, M | 2 |
| Chiang, SY | 1 |
| Wey, MT | 1 |
| Luo, YS | 1 |
| Shih, WC | 1 |
| Chimeddulam, D | 1 |
| Hsu, PC | 1 |
| Huang, HF | 1 |
| Tsai, TH | 1 |
| Wu, KY | 1 |
| Radic Savic, Z | 1 |
| Coric, V | 1 |
| Vidovic, S | 1 |
| Vidovic, V | 1 |
| Becarevic, J | 1 |
| Milovac, I | 1 |
| Reljic, Z | 1 |
| Mirjanic-Azaric, B | 1 |
| Skrbic, R | 1 |
| Gajanin, R | 1 |
| Matic, M | 1 |
| Simic, T | 1 |
| Kim, JY | 1 |
| Leem, J | 1 |
| Jeon, EJ | 1 |
| Chen, SM | 5 |
| Lin, CE | 2 |
| Chen, HH | 1 |
| Cheng, YF | 1 |
| Cheng, HW | 1 |
| Imai, K | 1 |
| Liu, L | 2 |
| Deng, Y | 1 |
| Cai, Y | 1 |
| Lu, P | 1 |
| Guo, Y | 1 |
| Zhang, C | 3 |
| Li, Q | 2 |
| Zhang, T | 1 |
| Han, M | 1 |
| Xu, G | 2 |
| Shan, H | 1 |
| Tian, W | 1 |
| Hong, Y | 1 |
| Xu, B | 1 |
| Wang, C | 3 |
| Yu, B | 1 |
| Tomlinson, T | 1 |
| Fernandes, A | 1 |
| Grollman, AP | 5 |
| Yu, Y | 1 |
| Hu, D | 1 |
| Zhou, Y | 1 |
| Xiang, H | 1 |
| Liu, B | 1 |
| Shen, L | 1 |
| Long, C | 1 |
| Liu, X | 3 |
| Lin, T | 1 |
| He, D | 1 |
| Xu, T | 1 |
| Zhang, D | 1 |
| Wei, G | 1 |
| Jin, C | 1 |
| Miao, X | 1 |
| Zhong, Y | 1 |
| Liu, Q | 1 |
| Zhu, J | 1 |
| Xia, X | 1 |
| Peng, X | 3 |
| Zhu, Z | 1 |
| Xu, X | 2 |
| Song, Y | 2 |
| Zhu, Y | 1 |
| Quan, W | 1 |
| Zhang, X | 4 |
| Bi, C | 1 |
| He, H | 1 |
| Li, S | 4 |
| Li, X | 3 |
| Ma, L | 1 |
| Shen, Z | 1 |
| Hu, H | 1 |
| Zhou, H | 2 |
| Yu, L | 1 |
| Jiang, H | 2 |
| Zeng, S | 1 |
| Lu, PH | 1 |
| Lee, HY | 1 |
| Liou, YL | 1 |
| Tung, SF | 1 |
| Kuo, KL | 1 |
| Chen, YH | 2 |
| Cao, L | 2 |
| Liu, H | 2 |
| Xie, W | 1 |
| Jiao, S | 1 |
| Wu, X | 3 |
| Yuan, K | 2 |
| Zhou, X | 2 |
| Yang, M | 1 |
| Guan, Y | 1 |
| Cai, H | 1 |
| Lai, Z | 1 |
| Lin, PY | 1 |
| Yang, WC | 1 |
| Huang, YS | 1 |
| Lin, TY | 1 |
| Chen, CM | 1 |
| Chen, HS | 1 |
| Lee, JA | 3 |
| Lin, F | 1 |
| Liu, Y | 5 |
| Tang, L | 1 |
| Chen, B | 2 |
| Ren, Y | 1 |
| Yang, X | 3 |
| Ji, H | 1 |
| Hu, J | 1 |
| Zhang, G | 1 |
| Song, J | 1 |
| Guo, D | 1 |
| Wang, P | 1 |
| Guo, W | 2 |
| Huang, G | 1 |
| Zhen, J | 1 |
| Li, T | 1 |
| Zhao, L | 1 |
| Tian, X | 1 |
| Huang, X | 1 |
| Feng, Y | 1 |
| Lei, H | 1 |
| Xu, A | 1 |
| Leung, JY | 1 |
| Wilson, HL | 1 |
| Voltzke, KJ | 1 |
| Williams, LA | 1 |
| Lee, HJ | 1 |
| Wobker, SE | 1 |
| Kim, WY | 2 |
| Duquesne, M | 1 |
| Declèves, AE | 2 |
| De Prez, E | 1 |
| Nortier, J | 4 |
| Colet, JM | 1 |
| Jadot, I | 1 |
| Colombaro, V | 1 |
| Martin, B | 1 |
| Habsch, I | 1 |
| Botton, O | 1 |
| Caron, N | 1 |
| Zeniya, M | 1 |
| Mori, T | 1 |
| Yui, N | 1 |
| Nomura, N | 1 |
| Mandai, S | 1 |
| Isobe, K | 1 |
| Chiga, M | 1 |
| Sohara, E | 1 |
| Rai, T | 1 |
| Uchida, S | 1 |
| Zhang, M | 1 |
| Mao, Y | 1 |
| Yu, F | 1 |
| Honarpisheh, M | 1 |
| Foresto-Neto, O | 1 |
| Steiger, S | 1 |
| Kraft, F | 1 |
| Koehler, P | 1 |
| von Rauchhaupt, E | 1 |
| Potempa, J | 1 |
| Adamowicz, K | 1 |
| Koziel, J | 1 |
| Lech, M | 1 |
| Zhang, HM | 1 |
| Zhao, XH | 1 |
| Sun, ZH | 1 |
| Li, GC | 1 |
| Liu, GC | 1 |
| Sun, LR | 1 |
| Hou, JQ | 1 |
| Zhou, W | 1 |
| Bastek, H | 1 |
| Zubel, T | 1 |
| Stemmer, K | 1 |
| Mangerich, A | 1 |
| Beneke, S | 1 |
| Dietrich, DR | 1 |
| Ye, J | 1 |
| Qian, Z | 1 |
| Xue, M | 1 |
| Zhu, S | 1 |
| Cai, D | 1 |
| Rui, J | 1 |
| Zhang, L | 5 |
| Song, MK | 1 |
| Lee, JH | 1 |
| Ryoo, IG | 1 |
| Lee, SH | 1 |
| Ku, SK | 1 |
| Kwak, MK | 1 |
| Gökmen, MR | 2 |
| Cosyns, JP | 7 |
| Arlt, VM | 8 |
| Stiborová, M | 8 |
| Phillips, DH | 4 |
| Schmeiser, HH | 10 |
| Simmonds, MS | 3 |
| Cook, HT | 1 |
| Vanherweghem, JL | 6 |
| Nortier, JL | 4 |
| Lord, GM | 3 |
| Huang, TC | 2 |
| Li, YC | 2 |
| Martínek, V | 3 |
| Frei, E | 4 |
| Lin, HH | 1 |
| Chou, SA | 1 |
| Yang, HY | 2 |
| Hwang, YH | 1 |
| Kuo, CH | 1 |
| Kao, TW | 1 |
| Lo, TC | 2 |
| Chen, PC | 3 |
| Mariappan, N | 1 |
| Megyesi, J | 1 |
| Shank, B | 1 |
| Kannan, K | 1 |
| Theus, S | 1 |
| Price, PM | 1 |
| Duffield, JS | 1 |
| Portilla, D | 1 |
| Michl, J | 2 |
| Jennings, HM | 1 |
| Kite, GC | 2 |
| Ingrouille, MJ | 1 |
| Heinrich, M | 2 |
| Liu, XH | 1 |
| Poon, SL | 1 |
| Pang, ST | 1 |
| McPherson, JR | 1 |
| Huang, KK | 1 |
| Guan, P | 1 |
| Weng, WH | 1 |
| Siew, EY | 1 |
| Heng, HL | 1 |
| Chong, SC | 1 |
| Gan, A | 1 |
| Tay, ST | 1 |
| Lim, WK | 1 |
| Cutcutache, I | 1 |
| Huang, D | 1 |
| Ler, LD | 1 |
| Nairismägi, ML | 1 |
| Lee, MH | 1 |
| Chang, YH | 1 |
| Yu, KJ | 1 |
| Chan-On, W | 1 |
| Li, BK | 1 |
| Yuan, YF | 1 |
| Qian, CN | 1 |
| Ng, KF | 1 |
| Wu, CF | 1 |
| Hsu, CL | 1 |
| Bunte, RM | 1 |
| Stratton, MR | 1 |
| Futreal, PA | 1 |
| Sung, WK | 1 |
| Chuang, CK | 1 |
| Ong, CK | 1 |
| Rozen, SG | 1 |
| Tan, P | 1 |
| Teh, BT | 1 |
| Feng, C | 1 |
| Xie, X | 1 |
| Wu, M | 1 |
| Gao, M | 1 |
| Qi, X | 4 |
| Ren, J | 6 |
| Huang, RF | 1 |
| Liang, QQ | 1 |
| Cheng, X | 1 |
| Long, Y | 1 |
| Wu, JY | 1 |
| Tian, Y | 1 |
| Gao, L | 1 |
| Zhao, H | 1 |
| Zhang, Z | 2 |
| Wu, G | 2 |
| Zeng, Y | 1 |
| Wu, J | 1 |
| Chen, W | 2 |
| Sun, H | 1 |
| Peng, W | 2 |
| Yu, X | 1 |
| Jelaković, B | 1 |
| Castells, X | 1 |
| Tomić, K | 1 |
| Ardin, M | 1 |
| Karanović, S | 1 |
| Zavadil, J | 1 |
| Luciano, RL | 1 |
| Perazella, MA | 1 |
| Neelisetty, S | 1 |
| Alford, C | 1 |
| Reynolds, K | 1 |
| Woodbury, L | 1 |
| Nlandu-Khodo, S | 1 |
| Yang, H | 1 |
| Fogo, AB | 1 |
| Hao, CM | 1 |
| Harris, RC | 1 |
| Zent, R | 1 |
| Gewin, L | 1 |
| Kathuria, P | 1 |
| Sharma, P | 1 |
| Abendong, MN | 1 |
| Wetmore, SD | 1 |
| Bunel, V | 2 |
| Antoine, MH | 2 |
| Duez, P | 2 |
| Stévigny, C | 2 |
| Samarakoon, R | 1 |
| Helo, S | 1 |
| Dobberfuhl, AD | 1 |
| Khakoo, NS | 1 |
| Falke, L | 1 |
| Overstreet, JM | 1 |
| Goldschmeding, R | 1 |
| Higgins, PJ | 1 |
| Dai, XY | 1 |
| Zhou, L | 2 |
| Huang, XR | 1 |
| Fu, P | 1 |
| Lan, HY | 1 |
| Chou, CY | 1 |
| Sun, CY | 1 |
| Wu, TK | 1 |
| Wei, CW | 1 |
| Pan, YR | 1 |
| Cherng, SH | 1 |
| Chang, WJ | 1 |
| Wang, HF | 1 |
| Yu, YL | 1 |
| Kanaan, N | 2 |
| Hassoun, Z | 1 |
| Raggi, C | 1 |
| Jadoul, M | 3 |
| Mourad, M | 1 |
| De Meyer, M | 1 |
| Aydin, S | 1 |
| Goffin, E | 2 |
| Bárta, F | 1 |
| Levová, K | 1 |
| Hodek, P | 1 |
| Wanke, S | 1 |
| Zierau, O | 1 |
| Vollmer, G | 1 |
| Neinhuis, C | 1 |
| Cheng, M | 1 |
| Xiao, H | 1 |
| Yi, JH | 1 |
| Han, SW | 1 |
| Kim, J | 1 |
| Park, MH | 1 |
| Shang, P | 1 |
| Li, XM | 2 |
| Tang, JW | 1 |
| Cai, SQ | 2 |
| Zou, J | 2 |
| Feng, JM | 3 |
| Li, W | 3 |
| Wang, LN | 1 |
| Shen, H | 1 |
| Lu, Y | 1 |
| Li, H | 1 |
| Ren, X | 1 |
| Nedelko, T | 1 |
| Hollstein, M | 2 |
| Lai, MN | 1 |
| Lai, JN | 1 |
| Tseng, WL | 1 |
| Chen, YY | 1 |
| Hwang, JS | 1 |
| Wang, JD | 2 |
| Chai, JJ | 1 |
| Chen, YP | 3 |
| Rui, HL | 1 |
| Bakhiya, N | 1 |
| Bahn, A | 1 |
| Burckhardt, G | 1 |
| Glatt, H | 1 |
| Xiao, Y | 4 |
| Xue, X | 5 |
| Wu, YF | 1 |
| Xin, GZ | 1 |
| Qian, Y | 1 |
| Xie, TP | 1 |
| Gong, LK | 2 |
| Shibutani, S | 2 |
| Bonala, RR | 1 |
| Rosenquist, T | 2 |
| Rieger, R | 1 |
| Suzuki, N | 2 |
| Johnson, F | 2 |
| Miller, F | 2 |
| Soderland, P | 1 |
| Lovekar, S | 1 |
| Weiner, DE | 1 |
| Brooks, DR | 1 |
| Kaufman, JS | 1 |
| Wu, HZ | 1 |
| Guo, L | 1 |
| Mak, YF | 1 |
| Liu, N | 1 |
| Poon, WT | 1 |
| Chan, YW | 1 |
| Cai, Z | 2 |
| Jiang, Z | 1 |
| Sun, L | 2 |
| Mei, X | 1 |
| Yong, B | 1 |
| Rosenquist, TA | 2 |
| Chau, W | 1 |
| Ross, R | 1 |
| Li, JY | 1 |
| Yong, TY | 1 |
| Klebe, S | 1 |
| Barbara, JA | 1 |
| Gong, L | 2 |
| Xing, G | 1 |
| Luan, Y | 2 |
| Wu, Y | 1 |
| Yao, J | 1 |
| Pan, G | 1 |
| Yang, L | 1 |
| Su, T | 1 |
| Meng, LQ | 1 |
| Zou, WZ | 1 |
| Wang, HY | 1 |
| Maeda, K | 2 |
| Qi, XM | 1 |
| Sugiyama, Y | 1 |
| Pozdzik, AA | 2 |
| Baudoux, T | 1 |
| Roumeguere, T | 1 |
| Pepeljnjak, S | 1 |
| Klarić, MŠ | 1 |
| Bai, Y | 1 |
| Sun, M | 1 |
| Ni, X | 1 |
| Zheng, S | 1 |
| Xu, F | 1 |
| Dai, S | 1 |
| Fu, W | 1 |
| Wang, H | 3 |
| Liang, Y | 1 |
| Yao, W | 1 |
| Ying, PH | 1 |
| Shi, X | 1 |
| Li, ZH | 1 |
| Wei, M | 1 |
| Ding, GF | 1 |
| Wang, DH | 1 |
| Ding, J | 1 |
| Chen, G | 1 |
| Chen, H | 2 |
| Peng, Y | 1 |
| Liu, F | 1 |
| Chen, D | 1 |
| Tang, Z | 1 |
| Luo, C | 1 |
| Rucevic, M | 1 |
| Breen, L | 1 |
| Clifton, J | 1 |
| Hixson, D | 1 |
| Josic, D | 1 |
| Tripatara, P | 1 |
| Onlamul, W | 1 |
| Booranasubkajorn, S | 1 |
| Wattanarangsan, J | 1 |
| Huabprasert, S | 1 |
| Lumlerdkij, N | 1 |
| Akarasereenont, P | 1 |
| Laohapand, T | 1 |
| Cao, YL | 1 |
| Li, WG | 1 |
| Fu, FT | 1 |
| Shi, XH | 1 |
| Jerabek, P | 1 |
| Dai, XW | 1 |
| Rao, XR | 1 |
| PETERS, G | 1 |
| HEDWALL, PR | 1 |
| Liu, MC | 1 |
| Maruyama, S | 1 |
| Mizuno, M | 1 |
| Morita, Y | 1 |
| Hanaki, S | 1 |
| Yuzawa, Y | 1 |
| Matsuo, S | 1 |
| Okada, H | 1 |
| Watanabe, Y | 1 |
| Inoue, T | 1 |
| Kobayashi, T | 1 |
| Kanno, Y | 1 |
| Shiota, G | 1 |
| Nakamura, T | 1 |
| Sugaya, T | 1 |
| Fukamizu, A | 1 |
| Suzuki, H | 1 |
| Roufosse, C | 1 |
| Pusey, CD | 1 |
| Cook, T | 1 |
| Isnard Bagnis, C | 1 |
| Deray, G | 1 |
| Baumelou, A | 1 |
| Le Quintrec, M | 1 |
| Lebeau, C | 1 |
| Debelle, FD | 2 |
| Pozdzik, A | 1 |
| De Prez, EG | 1 |
| Deschodt-Lanckman, MM | 2 |
| Yang, YF | 1 |
| Dong, H | 2 |
| Dong, HR | 1 |
| Qiu, CB | 1 |
| Wu, H | 1 |
| Liao, P | 1 |
| Ni, J | 1 |
| Pei, F | 1 |
| Grant, A | 1 |
| Ma, BY | 1 |
| Chen, HY | 1 |
| Wang, G | 1 |
| Wang, ZM | 1 |
| Sun, QS | 1 |
| Wang, HL | 1 |
| Zhang, JY | 1 |
| Huang, J | 1 |
| Mu, X | 1 |
| Fu, J | 1 |
| Zhou, Z | 1 |
| Ueda, S | 1 |
| Fan, MY | 1 |
| Tseng, CC | 1 |
| Ho, Y | 1 |
| Hsu, KY | 1 |
| Salmon, IJ | 1 |
| Decaestecker, C | 1 |
| Van den Branden, C | 1 |
| Verbeelen, D | 1 |
| Ge, M | 1 |
| Li, L | 2 |
| Luo, H | 1 |
| Xie, T | 1 |
| Gu, J | 1 |
| Vanhaelen, M | 1 |
| Vanhaelen-Fastre, R | 1 |
| But, P | 1 |
| Mengs, U | 1 |
| Stotzem, CD | 1 |
| Bieler, CA | 3 |
| Wiessler, M | 2 |
| van Ypersele de Strihou, C | 3 |
| Tanaka, A | 2 |
| Nishida, R | 2 |
| Sawai, K | 1 |
| Nagae, T | 1 |
| Shinkai, S | 1 |
| Ishikawa, M | 1 |
| Murata, M | 1 |
| Seta, K | 1 |
| Okuda, J | 1 |
| Yoshida, T | 2 |
| Sugawara, A | 1 |
| Kuwahara, T | 2 |
| Squifflet, JP | 1 |
| Wese, FX | 1 |
| Motoo, Y | 1 |
| Breuer, A | 1 |
| Koshikawa, M | 1 |
| Goto, M | 1 |
| Schwetz, BA | 1 |
| Thongkhao, K | 1 |
| Tungphatthong, C | 1 |
| Sukrong, S | 1 |
| Maggini, V | 1 |
| Menniti-Ippolito, F | 1 |
| Firenzuoli, F | 1 |
| Yamani, A | 1 |
| Husson, C | 1 |
| Elachouri, M | 1 |
| Zhang, H | 1 |
| Liu, J | 1 |
| Wei, X | 1 |
| Gao, Y | 1 |
| Guan, S | 1 |
| Lu, H | 1 |
| Liang, Q | 1 |
| Ni, C | 1 |
| Xie, M | 2 |
| Zhang, YX | 1 |
| Yan, XZ | 1 |
| Yang, MJ | 1 |
| Peng, SQ | 1 |
| Zhang, YZ | 1 |
| Rueda, DC | 1 |
| Zaugg, J | 1 |
| Quitschau, M | 1 |
| Reich, E | 1 |
| Hering, S | 1 |
| Hamburger, M | 1 |
| Yun, BH | 1 |
| Sidorenko, V | 1 |
| Iden, CR | 1 |
| Chen, CH | 1 |
| Pu, YS | 1 |
| Bonala, R | 1 |
| Dickman, KG | 1 |
| Turesky, RJ | 1 |
| Cui, L | 1 |
| Zhang, N | 1 |
| Zhou, SJ | 1 |
| Du, GY | 1 |
| Cui, HF | 1 |
| Wang, XR | 1 |
| Xiao, YQ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Renal and Cardiovascular Impairment in WTC Responders: Implications for Diagnosis and Treatment[NCT02246101] | 406 participants (Actual) | Observational | 2014-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for aristolochic acid i and Kidney Diseases
| Article | Year |
|---|---|
Aristolochic acid nephropathy: A scientometric analysis of literature published from 1971 to 2019.
Topics: Aristolochic Acids; Humans; Kidney; Kidney Diseases; Periodicals as Topic; Retrospective Studies | 2021 |
Recognition of the toxicity of aristolochic acid.
Topics: Age Factors; Aristolochic Acids; Carcinoma, Hepatocellular; Female; Humans; Kidney Diseases; Liver N | 2019 |
The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review.
Topics: Aristolochic Acids; Balkan Nephropathy; Humans; Kidney Diseases; Plant Preparations; Risk Factors; U | 2013 |
Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer.
Topics: Animals; Aristolochic Acids; Humans; Kidney Diseases; Neoplasms, Glandular and Epithelial; Oxidoredu | 2013 |
[Aristolochic acid nephropathy: an issue worth more attention].
Topics: Animals; Aristolochic Acids; Autophagy; Drugs, Chinese Herbal; Epithelial-Mesenchymal Transition; Hu | 2013 |
Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid.
Topics: Animals; Aristolochic Acids; Carcinogens; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; DNA Addu | 2014 |
Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment.
Topics: Animals; Aristolochia; Aristolochic Acids; Disease Progression; Glucocorticoids; Humans; Kidney Dise | 2015 |
Chronic kidney disease associated with environmental toxins and exposures.
Topics: Aristolochic Acids; Balkan Nephropathy; Chronic Disease; Drugs, Chinese Herbal; Endemic Diseases; En | 2010 |
«Suspects» in etiology of endemic nephropathy: aristolochic acid versus mycotoxins.
Topics: Animals; Aristolochic Acids; Drugs, Chinese Herbal; Humans; Kidney Diseases; Mycotoxins | 2010 |
Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.
Topics: Aristolochic Acids; Balkan Nephropathy; DNA Adducts; Humans; Iatrogenic Disease; Kidney Cortex; Kidn | 2013 |
[Current status of injury caused by Chinese herbal medicine and its counter measure].
Topics: Aristolochia; Aristolochic Acids; Drug Contamination; Drugs, Chinese Herbal; Humans; Kidney Diseases | 2001 |
Aristolochic acid nephropathy: what we know and what we have to do.
Topics: Aristolochic Acids; Drugs, Chinese Herbal; Humans; Kidney Diseases | 2004 |
Herbs and the kidney.
Topics: Aristolochic Acids; Beverages; Drugs, Chinese Herbal; Fanconi Syndrome; Humans; Hyperkalemia; Hypert | 2004 |
[Advances in studies on pharmacokinetics of aristolochic acid I].
Topics: Administration, Oral; Animals; Aristolochia; Aristolochic Acids; Dose-Response Relationship, Drug; H | 2006 |
132 other studies available for aristolochic acid i and Kidney Diseases
| Article | Year |
|---|---|
Study on the potential nephrotoxicity and mutagenicity of aristolochic acid IVa and its mechanism.
Topics: Animals; Aristolochic Acids; Carcinogens; Dose-Response Relationship, Drug; Female; Kidney Diseases; | 2021 |
Involvement of REV-ERBα dysregulation and ferroptosis in aristolochic acid I-induced renal injury.
Topics: Animals; Aristolochic Acids; Cell Line; Cell Survival; Epithelial Cells; Ferroptosis; Gene Expressio | 2021 |
Macrophage-derived, LRG1-enriched extracellular vesicles exacerbate aristolochic acid nephropathy in a TGFβR1-dependent manner.
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Extracellular Vesicles; Glycoproteins; Humans; | 2022 |
Dissection of Targeting Molecular Mechanisms of Aristolochic Acid-induced Nephrotoxicity
Topics: Aristolochic Acids; Female; Humans; Kidney; Kidney Diseases; Male; Metabolomics | 2022 |
Schisandra chinensis Oil Attenuates Aristolochic Acid I-Induced Nephrotoxicity in vivo and in vitro.
Topics: Animals; Apoptosis; Aristolochic Acids; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Glutathion | 2022 |
Synergistic Interaction of Polycyclic Aromatic Hydrocarbons, Phthalate Esters, or Phenol on DNA Adduct Formation by Aristolochic Acid I: Insights into the Etiology of Balkan Endemic Nephropathy.
Topics: Aristolochic Acids; Balkan Nephropathy; Coal; DNA Adducts; Esters; Female; Humans; Kidney Diseases; | 2022 |
MicroRNA-382 Promotes M2-Like Macrophage
Topics: Animals; Aristolochic Acids; Fibrosis; Kidney Diseases; Macrophage Activation; Macrophages; Mice; Mi | 2022 |
Curcumin alleviates aristolochic acid nephropathy based on SIRT1/Nrf2/HO-1 signaling pathway.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Apoptosis; Aristolochic Acids; bcl-2-Associated X Pro | 2022 |
Growing risk of aristolochic acid nephropathy in the era of COVID-19 - Correspondence.
Topics: Aristolochic Acids; COVID-19; Humans; Kidney Diseases | 2022 |
Bioaccumulation and DNA Adduct Formation of Aristolactam I: Unmasking a Toxicological Mechanism in the Pathophysiology of Aristolochic Acid Nephropathy.
Topics: Aristolochic Acids; Bioaccumulation; Carcinogens; DNA Adducts; Humans; Kidney Diseases; Neoplasms | 2023 |
Aristolochic acid induces an inflammatory response with prostaglandin E2 production and apoptosis in NRK-52E proximal tubular cells.
Topics: Animals; Apoptosis; Aristolochic Acids; Carcinoma, Transitional Cell; Cell Line; Cyclooxygenase 2; D | 2023 |
Effects of Diet on Aristolochic Acid-DNA Adduct Formation: Implications for Balkan Endemic Nephropathy Etiology.
Topics: Aristolochic Acids; Balkan Nephropathy; Diet; DNA Adducts; Humans; Kidney Diseases; Neoplasms | 2023 |
Differences in p38-STAT3-S100A11 signaling after the administration of aristolochic acid I and IVa may account for the disparity in their nephrotoxicity.
Topics: Animals; Aristolochic Acids; Fibrosis; Kidney; Kidney Diseases; Mice; Proteomics; S100 Proteins; Sig | 2023 |
Study on the difference and correlation between the contents and toxicity of aristolochic acid analogues in Aristolochia plants.
Topics: Animals; Aristolochia; Aristolochic Acids; Chromatography, High Pressure Liquid; Drugs, Chinese Herb | 2023 |
Simultaneous toxicokinetic studies of aristolochic acid I and II and aristolactam I and II using a newly-developed microdialysis liquid chromatography-tandem mass spectrometry.
Topics: Animals; Aristolochic Acids; Balkan Nephropathy; Chromatography, Liquid; Kidney Diseases; Microdialy | 2023 |
Topics: Balkan Nephropathy; Carcinoma, Transitional Cell; Female; Glutathione Peroxidase; Humans; Kelch-Like | 2023 |
Protective Effects of Melatonin Against Aristolochic Acid-Induced Nephropathy in Mice.
Topics: Animals; Apoptosis; Aristolochic Acids; Cytokines; Humans; Kidney; Kidney Diseases; Male; Melatonin; | 2019 |
Effect of prednisolone on glyoxalase 1 in an inbred mouse model of aristolochic acid nephropathy using a proteomics method with fluorogenic derivatization-liquid chromatography-tandem mass spectrometry.
Topics: Animals; Aristolochic Acids; Chromatography, High Pressure Liquid; Disease Models, Animal; Female; F | 2020 |
Ablation of Gsa impairs renal tubule proliferation after injury via CDK2/cyclin E.
Topics: Animals; Aristolochic Acids; Cell Line; Cell Proliferation; Cyclic AMP; Cyclic AMP-Dependent Protein | 2020 |
Clinicopathologic characteristics and prognosis of upper tract urothelial carcinoma complicated with aristolochic acid nephropathy after radical nephroureterectomy.
Topics: Adult; Aged; Aged, 80 and over; Aristolochic Acids; Drugs, Chinese Herbal; Female; Humans; Kidney Di | 2020 |
Topics: Aristolochia; Aristolochic Acids; Carcinogens; Gout; Gout Suppressants; History; Humans; Iatrogenic | 2020 |
Human umbilical cord mesenchymal stem cell attenuates renal fibrosis via TGF-β/Smad signaling pathways in vivo and in vitro.
Topics: Animals; Aristolochic Acids; Cell Line; Coculture Techniques; Disease Models, Animal; Epithelial-Mes | 2020 |
The renoprotective effect of diosgenin on aristolochic acid I-induced renal injury in rats: impact on apoptosis, mitochondrial dynamics and autophagy.
Topics: Animals; Apoptosis; Aristolochic Acids; Autophagy; Caspase 3; Diosgenin; Dynamins; Humans; Kidney; K | 2020 |
Integrative microRNA and mRNA expression profiling in acute aristolochic acid nephropathy in mice.
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regu | 2020 |
Effects of rhein and Rheum palmatum L. extract on the pharmacokinetics and tissue distribution of aristolochic acid I and its demethylated metabolite in rats.
Topics: Animals; Anthraquinones; Aristolochic Acids; Biotransformation; Demethylation; Injections, Intraveno | 2021 |
Nephroprotective Role of Zhibai Dihuang Wan in Aristolochic Acid-Intoxicated Zebrafish.
Topics: Animals; Animals, Genetically Modified; Aristolochic Acids; Drugs, Chinese Herbal; Gene Expression P | 2020 |
Real-time monitoring of aristolochic acid I reduction process using surface-enhanced Raman Spectroscopy with DFT simulation.
Topics: Aristolochic Acids; Biosensing Techniques; DNA Adducts; Humans; Kidney Diseases; Spectrum Analysis, | 2021 |
Evaluation of the nephrotoxicity and safety of low-dose aristolochic acid, extending to the use of Xixin (Asurum), by determination of methylglyoxal and d-lactate.
Topics: Animals; Aristolochic Acids; Collagen; Disease Models, Animal; Drugs, Chinese Herbal; Female; Fibros | 2021 |
Rapamycin protects against aristolochic acid nephropathy in mice by potentiating mammalian target of rapamycin‑mediated autophagy.
Topics: Animals; Apoptosis; Aristolochic Acids; Autophagy; Cell Line; Disease Models, Animal; Humans; Kidney | 2021 |
Berberine-Based Heterogeneous Linear Supramolecules Neutralized the Acute Nephrotoxicity of Aristolochic Acid by the Self-Assembly Strategy.
Topics: Animals; Aristolochic Acids; Berberine; Drug Interactions; Drugs, Chinese Herbal; Dysbiosis; Gastroi | 2021 |
Topics: Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Animals; Aristolochic Acids; Cell Cycle P | 2017 |
Interest of metabonomic approach in environmental nephrotoxicants: Application to aristolochic acid exposure.
Topics: Animals; Aristolochic Acids; Environmental Pollutants; Kidney Diseases; Male; Metabolomics; Pilot Pr | 2017 |
Restored nitric oxide bioavailability reduces the severity of acute-to-chronic transition in a mouse model of aristolochic acid nephropathy.
Topics: Animals; Arginine; Aristolochic Acids; Biological Availability; Inflammation; Kidney Diseases; Mice; | 2017 |
The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1.
Topics: Animals; Aristolochic Acids; Bortezomib; Disease Models, Animal; Fibrosis; Kidney; Kidney Diseases; | 2017 |
The potential role of aquaporin 1 on aristolochic acid I induced epithelial mesenchymal transition on HK-2 cells.
Topics: Aquaporin 1; Aristolochic Acids; Cell Line; Epithelial-Mesenchymal Transition; Extracellular Signal- | 2018 |
Aristolochic acid I determine the phenotype and activation of macrophages in acute and chronic kidney disease.
Topics: Acute Kidney Injury; Animals; Aristolochic Acids; Cisplatin; Disease Models, Animal; Female; Fibrosi | 2018 |
Comparison of Aristolochic acid I derived DNA adduct levels in human renal toxicity models.
Topics: Activation, Metabolic; Aged; Animals; Aristolochic Acids; Cell Survival; DNA Adducts; Female; HEK293 | 2019 |
Aristolochic acid I aggravates renal injury by activating the C3a/C3aR complement system.
Topics: Animals; Aristolochic Acids; Cell Line; Complement C3a; Gene Expression Regulation; Humans; Kidney D | 2019 |
Bardoxolone ameliorates TGF-β1-associated renal fibrosis through Nrf2/Smad7 elevation.
Topics: Animals; Aristolochic Acids; Cell Line; Extracellular Matrix; Fibrosis; Gene Expression Regulation; | 2019 |
Urinary d-lactate levels reflect renal function in aristolochic acid-induced nephropathy in mice.
Topics: Acetylglucosaminidase; Animals; Aristolochic Acids; Creatinine; Female; Histocytochemistry; Kidney; | 2013 |
Association of blood lead and mercury with estimated GFR in herbalists after the ban of herbs containing aristolochic acids in Taiwan.
Topics: Adult; Aristolochiaceae; Aristolochic Acids; Arsenic; Cadmium; Cross-Sectional Studies; Glomerular F | 2013 |
Proximal tubule PPARα attenuates renal fibrosis and inflammation caused by unilateral ureteral obstruction.
Topics: Animals; Arginase; Aristolochic Acids; B7-2 Antigen; Collagen Type I; Collagen Type IV; Down-Regulat | 2013 |
Is aristolochic acid nephropathy a widespread problem in developing countries? A case study of Aristolochia indica L. in Bangladesh using an ethnobotanical-phytochemical approach.
Topics: Aristolochia; Aristolochic Acids; Bangladesh; Developing Countries; Ethnobotany; Ethnopharmacology; | 2013 |
Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
Topics: Animals; Aristolochic Acids; Carcinogens; Cell Line, Tumor; Genome, Human; Humans; Kidney Diseases; | 2013 |
Tanshinone I protects mice from aristolochic acid I-induced kidney injury by induction of CYP1A.
Topics: Abietanes; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Aristolochic Acids; Blood C | 2013 |
[Effect of fermented cordyceps powder and prednisone on the Notch2/Hes-1 signaling activation in the kidney tubules of rats with acute aristolochic acid nephropathy].
Topics: Animals; Apoptosis; Aristolochic Acids; Basic Helix-Loop-Helix Transcription Factors; Cordyceps; Fem | 2013 |
Expression of histone deacetylase-1 and p300 in aristolochic acid nephropathy models.
Topics: Actins; Animals; Aristolochic Acids; Dose-Response Relationship, Drug; E1A-Associated p300 Protein; | 2014 |
Autophagy inhibitors promoted aristolochic acid I induced renal tubular epithelial cell apoptosis via mitochondrial pathway but alleviated nonapoptotic cell death in mouse acute aritolochic acid nephropathy model.
Topics: Adenine; Animals; Apoptosis; Aristolochia; Aristolochic Acids; Autophagy; Chloroquine; Drugs, Chines | 2014 |
Increased renal semicarbazide-sensitive amine oxidase activity and methylglyoxal levels in aristolochic acid-induced nephrotoxicity.
Topics: Amine Oxidase (Copper-Containing); Animals; Aristolochic Acids; Dose-Response Relationship, Drug; Ki | 2014 |
Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.
Topics: Adult; Aged; Aristolochic Acids; Balkan Nephropathy; Carcinogens; Carcinoma, Renal Cell; Exome; Fema | 2015 |
Renal fibrosis is not reduced by blocking transforming growth factor-β signaling in matrix-producing interstitial cells.
Topics: Actins; Animals; Aristolochic Acids; Cells, Cultured; Collagen Type I; Disease Models, Animal; Extra | 2015 |
Conformational preferences of DNA following damage by aristolochic acids: Structural and energetic insights into the different mutagenic potential of the ALI and ALII-N(6)-dA adducts.
Topics: Animals; Aristolochic Acids; DNA Adducts; Humans; Kidney Diseases; Molecular Dynamics Simulation; Nu | 2015 |
In vitro effects of Panax ginseng in aristolochic acid-mediated renal tubulotoxicity: apoptosis versus regeneration.
Topics: Apoptosis; Aristolochia; Aristolochic Acids; beta Catenin; Caspase 3; Cell Cycle; Cell Line; Cell Pr | 2015 |
Loss of tumour suppressor PTEN expression in renal injury initiates SMAD3- and p53-dependent fibrotic responses.
Topics: Animals; Apoptosis; Aristolochic Acids; Cell Cycle Checkpoints; Cell Line; Cell Proliferation; Disea | 2015 |
Smad7 protects against chronic aristolochic acid nephropathy in mice.
Topics: Animals; Aristolochic Acids; Blotting, Western; Disease Models, Animal; Drugs, Chinese Herbal; Gene | 2015 |
Impairment of the Cellular Distribution and Stability of the Erythropoietin Receptor Through the Direct Targeting of Aristolochic Acid.
Topics: Anemia; Animals; Aristolochic Acids; Cell Line; Cell Membrane; Humans; Kidney Diseases; Lysosomes; M | 2015 |
Vitamin C attenuates the toxic effect of aristolochic acid on renal tubular cells via decreasing oxidative stress‑mediated cell death pathways.
Topics: Animals; Apoptosis; Aristolochia; Aristolochic Acids; Asarum; Ascorbic Acid; Caspase 3; Cell Line; D | 2015 |
Long-term Outcome of Kidney Recipients Transplanted for Aristolochic Acid Nephropathy.
Topics: Adult; Aged; Aristolochic Acids; Belgium; Carcinoma; Drug Therapy, Combination; Female; Graft Reject | 2016 |
A Mechanism of O-Demethylation of Aristolochic Acid I by Cytochromes P450 and Their Contributions to This Reaction in Human and Rat Livers: Experimental and Theoretical Approaches.
Topics: Activation, Metabolic; Animals; Aristolochic Acids; Catalysis; Catalytic Domain; Cytochrome P-450 En | 2015 |
LC-MS- and (1)H NMR-Based Metabolomic Analysis and in Vitro Toxicological Assessment of 43 Aristolochia Species.
Topics: Aristolochia; Aristolochic Acids; Chromatography, Liquid; Drugs, Chinese Herbal; Humans; Kidney Dise | 2016 |
Acute nephrotoxicity of aristolochic acid in vitro: metabolomics study for intracellular metabolic time-course changes.
Topics: Aristolochia; Aristolochic Acids; Biomarkers; Cell Line; Chromatography, High Pressure Liquid; Disea | 2016 |
Effects of aristolochic acid I and/or hypokalemia on tubular damage in C57BL/6 rat with aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Disease Models, Animal; Hypokalemia; Kidney Diseases; Kidney Tubules; M | 2018 |
[Observation of penetration, distribution and accumulation in human renal proximal tubular epithelial cells by aristololactam-I].
Topics: Animals; Aristolochic Acids; Cell Line; Cell Nucleus; Cytoplasm; Epithelial Cells; Humans; Kidney Di | 2008 |
[Differentiation of mesenchymal stem cells into vascular endothelial cells in treatment of chronic aristolochic acid nephropathy: experiment with rats].
Topics: Animals; Aristolochic Acids; Bone Marrow Cells; Cell Differentiation; Endothelial Cells; Endothelium | 2008 |
TGF-beta1/Smad7 signaling stimulates renal tubulointerstitial fibrosis induced by AAI.
Topics: Actins; Animals; Aristolochic Acids; Benzamides; Cells, Cultured; Dioxoles; Down-Regulation; Epithel | 2008 |
TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours.
Topics: Aristolochic Acids; Carcinogens; Codon; DNA Mutational Analysis; DNA, Neoplasm; Exons; Genes, p53; G | 2009 |
Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid.
Topics: Adult; Aged; Aristolochic Acids; Chronic Disease; Drugs, Chinese Herbal; Female; Follow-Up Studies; | 2009 |
Increased mortality risk for cancers of the kidney and other urinary organs among Chinese herbalists.
Topics: Adolescent; Adult; Aristolochic Acids; Asian People; Carcinogens; Cohort Studies; Female; Health Sur | 2009 |
[Effects of Hirsutella sinensis on TGF-beta1 and Snail expressions and transdifferentiation of tubular epithelial-myofibroblast in renal tissue of rats with chronic aristolochic acid nephropathy].
Topics: Actins; Animals; Aristolochic Acids; Cell Transdifferentiation; Chronic Disease; Cordyceps; Drugs, C | 2009 |
Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Cells, Cultured; DNA Adducts; Extracellular Space; Female; Humans; Kidn | 2009 |
beta-Naphthoflavone protects mice from aristolochic acid-I-induced acute kidney injury in a CYP1A dependent mechanism.
Topics: Acute Disease; Animals; Aristolochic Acids; beta-Naphthoflavone; Cytochrome P-450 CYP1A1; Cytochrome | 2009 |
Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents.
Topics: Animals; Aristolochic Acids; Carcinogens; Chromatography, High Pressure Liquid; DNA; DNA Adducts; In | 2010 |
Proteomics investigation on aristolochic acid nephropathy: a case study on rat kidney tissues.
Topics: Amino Acid Sequence; Animals; Aristolochic Acids; Biomarkers; DNA Adducts; Electrophoresis, Gel, Two | 2011 |
Inhibition of aquaporin-1 expression by RNAi protects against aristolochic acid I-induced apoptosis in human proximal tubular epithelial (HK-2) cells.
Topics: Apoptosis; Aquaporin 1; Aristolochic Acids; Cell Line; Epithelial Cells; Humans; Kidney Diseases; Ki | 2011 |
Genetic loci that affect aristolochic acid-induced nephrotoxicity in the mouse.
Topics: Analysis of Variance; Animals; Aristolochic Acids; Carcinogens; Genetic Loci; Genotype; Kidney; Kidn | 2011 |
Nephropathy associated with use of a Chinese herbal product containing aristolochic acid.
Topics: Aged; Aristolochic Acids; Drugs, Chinese Herbal; Fatal Outcome; Fibrosis; Humans; Kidney Diseases; K | 2011 |
Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity.
Topics: Animals; Aristolochic Acids; Dicumarol; Enzyme Inhibitors; Epithelial Cells; Gene Expression; Kidney | 2011 |
Aristolochic acid nephropathy: variation in presentation and prognosis.
Topics: Aristolochic Acids; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Diseases; Male; M | 2012 |
Critical role of organic anion transporters 1 and 3 in kidney accumulation and toxicity of aristolochic acid I.
Topics: Animals; Aristolochic Acids; HEK293 Cells; Humans; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred | 2011 |
Risk of urinary tract carcinoma in aristolochic acid nephropathy.
Topics: Aristolochic Acids; Female; Humans; Kidney Diseases; Male; Mutagens | 2012 |
Glutathione S-transferases T1 null genotype is associated with susceptibility to aristolochic acid nephropathy.
Topics: Adult; Aged; Aristolochic Acids; Asian People; ATP Binding Cassette Transporter, Subfamily B, Member | 2012 |
Renal microvascular injury in chronic aristolochic acid nephropathy and protective effects of Cozaar.
Topics: Animals; Aristolochic Acids; Chronic Disease; Kidney; Kidney Diseases; Losartan; Male; Microvessels; | 2012 |
[Clinical characteristics and long-term follow-up analysis of three cases with newborn aristolochic acid nephropathy].
Topics: Aristolochic Acids; Drugs, Chinese Herbal; Female; Follow-Up Studies; Glomerular Filtration Rate; Hu | 2011 |
[Experts comment].
Topics: Aristolochic Acids; Drugs, Chinese Herbal; Female; Follow-Up Studies; Glomerular Filtration Rate; Hu | 2011 |
Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts.
Topics: Animals; Aristolochic Acids; Cell Line; Cell Proliferation; Extracellular Matrix; Fibroblasts; Fibro | 2012 |
Aristolochic acid nephropathy.
Topics: Aristolochic Acids; Balkan Nephropathy; Carcinogens; Drugs, Chinese Herbal; Humans; Kidney Diseases; | 2012 |
Clinical and pathological spectrums of aristolochic acid nephropathy.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aristolochic Acids; Biomarkers; Biopsy; Chi-Square Dis | 2012 |
Proteome alterations in response to aristolochic acids in experimental animal model.
Topics: Animals; Aristolochic Acids; Biomarkers, Tumor; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred DB | 2012 |
The safety of Homnawakod herbal formula containing Aristolochia tagala Cham. in Wistar rats.
Topics: Animals; Aristolochia; Aristolochic Acids; Blood Pressure; Chemical and Drug Induced Liver Injury; C | 2012 |
Transitional cell carcinoma associated with aristolochic acid nephropathy: most common cancer in chronic hemodialysis patients in China.
Topics: Adult; Aged; Aged, 80 and over; Aristolochic Acids; Carcinoma, Transitional Cell; China; Female; Hum | 2012 |
Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
Topics: Amino Acid Sequence; Aristolochia; Aristolochic Acids; Aryl Hydrocarbon Hydroxylases; Catalytic Doma | 2012 |
The importance of a histology-based diagnosis of interstitial nephropathy in two patients with renal insufficiency.
Topics: Aged; Aristolochic Acids; Carcinoma, Transitional Cell; Drugs, Chinese Herbal; Female; Humans; Kidne | 2003 |
ARISTOLOCHIC ACID INTOXICATION: A NEW TYPE OF IMPAIRMENT OF URINARY CONCENTRATING ABILITY.
Topics: Aristolochic Acids; Blood Chemical Analysis; Creatine; Creatinine; Electrolytes; Kidney Diseases; Ki | 1963 |
The nephrotoxicity of Aristolochia manshuriensis in rats is attributable to its aristolochic acids.
Topics: Animals; Apoptosis; Aristolochia; Aristolochic Acids; Cell Division; Creatinine; Female; Kidney; Kid | 2003 |
Transgene-derived hepatocyte growth factor attenuates reactive renal fibrosis in aristolochic acid nephrotoxicity.
Topics: Animals; Aristolochic Acids; Fibrosis; Growth Substances; Hepatocyte Growth Factor; Kidney; Kidney D | 2003 |
DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy.
Topics: Aristolochia; Aristolochic Acids; Breast Neoplasms; DNA Adducts; Female; Genes, p53; Humans; Kidney | 2004 |
Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies.
Topics: Acetylglucosaminidase; Albumins; Animals; Aristolochic Acids; Biomarkers; Carcinogens; Chromatograph | 2005 |
[Protective effects of yishen ruanjian power on renal interstitial fribrosis in chronic aristolochic acid induced nephropathy rat model].
Topics: Animals; Aristolochic Acids; beta 2-Microglobulin; Creatinine; Drugs, Chinese Herbal; Fibrosis; Kidn | 2005 |
[The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy].
Topics: Animals; Aristolochic Acids; Bosentan; Collagen Type I; Connective Tissue Growth Factor; Disease Mod | 2005 |
NMR-based metabonomic study on the subacute toxicity of aristolochic acid in rats.
Topics: Animals; Aristolochic Acids; Blood Chemical Analysis; Body Weight; Chemical and Drug Induced Liver I | 2006 |
"Chinese herbal uropathy and nephropathy"?
Topics: Aristolochic Acids; Carcinogens; Drugs, Chinese Herbal; Humans; Kidney Diseases | 2006 |
[Effects of glycyrrihizic acid and prednisone on pathological and ultrastructural changes of kidney in rats with chronic aristolochic acid nephropathy].
Topics: Animals; Anti-Inflammatory Agents; Aristolochic Acids; Chronic Disease; Drug Therapy, Combination; G | 2007 |
In vitro cytotoxicity assay with selected chemicals using human cells to predict target-organ toxicity of liver and kidney.
Topics: Acetaminophen; Aristolochic Acids; Cadmium Chloride; Cell Line; Cell Survival; Chemical and Drug Ind | 2007 |
Selective toxicity of aristolochic acids I and II.
Topics: Animals; Aristolochic Acids; Carcinogens; Cell Transformation, Neoplastic; DNA Adducts; Fibrosis; Ki | 2007 |
Pharmacokinetics and nephrotoxicity of aristolochic acid in rabbits.
Topics: Animals; Aristolochic Acids; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; | 2007 |
Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation.
Topics: Animals; Apoptosis; Aristolochic Acids; Cell Proliferation; Chemokine CCL2; Collagen; Discoidin Doma | 2008 |
Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity.
Topics: Animals; Aristolochic Acids; Carcinogens; Cell Fractionation; Inactivation, Metabolic; Kidney Diseas | 2008 |
[Study on homologous bone marrow mesenchymal stem cells in repairing peri-tubular capillary cluster].
Topics: Animals; Antigens, CD34; Aristolochic Acids; Blotting, Western; Bone Marrow Cells; Bone Marrow Trans | 2008 |
Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid.
Topics: Animals; Aristolochic Acids; Carcinogens; Inactivation, Metabolic; Kidney Diseases; Liver; Mice; NAD | 2008 |
Identification of aristolochic acid in Chinese herbs.
Topics: Alkaloids; Aristolochic Acids; Belgium; Benzylisoquinolines; Drugs, Chinese Herbal; Humans; Kidney D | 1994 |
Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology.
Topics: Animals; Aristolochic Acids; Body Weight; Carcinogens; Creatinine; Dose-Response Relationship, Drug; | 1993 |
Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy.
Topics: Adult; Aristolochic Acids; DNA Adducts; Drugs, Chinese Herbal; Female; Humans; Kidney; Kidney Diseas | 1996 |
32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy.
Topics: Adult; Animals; Aristolochic Acids; DNA Adducts; Drugs, Chinese Herbal; Female; Humans; Kidney Disea | 1997 |
[Traditional remedy-induced Chinese herbs nephropathy showing rapid deterioration of renal function].
Topics: Adult; Aristolochic Acids; Drugs, Chinese Herbal; Female; Humans; Kidney; Kidney Diseases; Phenanthr | 1997 |
Urothelial lesions in Chinese-herb nephropathy.
Topics: Adult; Aristolochic Acids; Carcinogens; Carcinoma in Situ; Carcinoma, Transitional Cell; Drugs, Chin | 1999 |
[On Chinese herbs neuropathy].
Topics: Aristolochic Acids; Drugs, Chinese Herbal; Humans; Kidney Diseases; Phenanthrenes; Terminology as To | 1999 |
Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy.
Topics: Animals; Aristolochic Acids; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; D | 1999 |
Outbreak of Chinese herb nephropathy in Japan: are there any differences from Belgium?
Topics: Aristolochic Acids; Asian People; Belgium; Calcitriol; Disease Outbreaks; Drugs, Chinese Herbal; Fan | 2001 |
From the Food and Drug Administration.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Aristolochic Acids; Arrhythmias, Cardiac; C | 2001 |
When is "aristolochic acid nephropathy" more accurate than "Chinese herbs nephropathy"?
Topics: Aristolochic Acids; Drugs, Chinese Herbal; Humans; Kidney Diseases; Phenanthrenes; Terminology as To | 2002 |
A PCR-lateral flow immunochromatographic assay (PCR-LFA) for detecting Aristolochia species, the plants responsible for aristolochic acid nephropathy.
Topics: Aristolochia; Aristolochic Acids; Immunoassay; Kidney Diseases; Polymerase Chain Reaction | 2022 |
Aristolochia, a nephrotoxic herb, still surfs on the Web, 15 years later.
Topics: Aristolochia; Herbal Medicine; Humans; Internet; Kidney Diseases | 2018 |
Substitution between Aristolochia and Bryonia genus in North-Eastern Morocco: toxicological implications.
Topics: Actins; Aristolochia; beta Catenin; Bryonia; Cadherins; Cell Line; Cell Survival; Down-Regulation; E | 2015 |
Omeprazole Alleviates Aristolochia manshuriensis Kom-Induced Acute Nephrotoxicity.
Topics: Acute Disease; Animals; Aristolochia; Aristolochic Acids; Cytochrome P-450 CYP1A1; Epithelial Cells; | 2016 |
Comparative 28-day repeated oral toxicity of Longdan Xieganwan, Akebia trifoliate (Thunb.) koidz., Akebia quinata (Thunb.) Decne. and Caulis aristolochiae manshuriensis in mice.
Topics: Administration, Oral; Animals; Aristolochia; Body Weight; Dose-Response Relationship, Drug; Drugs, C | 2008 |
[Nephrotoxicity study of Aristolochia fangchi in rats by metabonomics].
Topics: Animals; Aristolochia; Blood Urea Nitrogen; Creatinine; Drugs, Chinese Herbal; Kidney Diseases; Kidn | 2009 |
Discovery of GABA(A) receptor modulator aristolactone in a commercial sample of the Chinese herbal drug "Chaihu" (Bupleurum chinense roots) unravels adulteration by nephrotoxic Aristolochia manshuriensis roots.
Topics: Animals; Aristolochia; Aristolochic Acids; Bupleurum; Drug Contamination; Drugs, Chinese Herbal; Hum | 2012 |
Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry.
Topics: Adult; Aged; Animals; Aristolochia; Aristolochic Acids; Balkan Nephropathy; Chromatography, Liquid; | 2012 |
Isogenic mesenchymal stem cells transplantation improves a rat model of chronic aristolochic acid nephropathy via upregulation of hepatic growth factor and downregulation of transforming growth factor β1.
Topics: Animals; Aristolochia; Aristolochic Acids; Bone Marrow Cells; Down-Regulation; Female; Fibrosis; Hep | 2012 |
Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry.
Topics: Aerobiosis; Animals; Aristolochia; Aristolochic Acids; Biotransformation; Chromatography, High Press | 2006 |
[The nephrotoxicity in rats caused by Longdan Xiegan decoction].
Topics: Acetylglucosaminidase; Animals; Aristolochia; beta 2-Microglobulin; Blood Urea Nitrogen; Creatinine; | 2006 |
[Study on transdifferentiation of renal tubular cells in rat chronic renal interstitial fibrosis induced by Radix Aristolochiae Fangchi Extract].
Topics: Actins; Animals; Aristolochia; Aristolochic Acids; Cell Transdifferentiation; Cytokines; Drugs, Chin | 2006 |